Form 4: BioXcel Director June Bray Granted Stock Options

BioXcel Therapeutics Director June Bray was granted 17,000 stock options with an exercise price of $2.01, vesting based on continued service.

Summary

• June Bray, a Director of BioXcel Therapeutics, Inc. (BTAI), was granted 17,000 stock options.
• The transaction date for this grant was January 9, 2026.
• The exercise price for these stock options is $2.01 per share.
• Each option represents the right to buy one share of BioXcel Therapeutics Common Stock.
• The options will vest and become exercisable on the earlier of the first anniversary of the grant date (January 9, 2027) or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the grant date.
• Vesting is contingent upon June Bray's continued service as a non-employee director through the vesting date.
• The stock options have an expiration date of January 9, 2036.
• Following this transaction, June Bray beneficially owns 17,000 derivative securities (stock options) directly.

Sentiment

Score: 6

Explanation: The filing reports a routine compensation event for a director, which is generally a neutral to slightly positive signal as it aligns management interests with shareholders. There are no negative implications from this specific transaction.

Positives

• The grant of stock options aligns the director's financial interests with those of the shareholders, incentivizing long-term company performance.
• This is a standard form of compensation for non-employee directors, indicating normal corporate governance practices.

Future Outlook

The vesting schedule for the granted stock options indicates an expectation for June Bray's continued service as a non-employee director for at least one year or until the next annual stockholders' meeting, aligning her future incentives with the company's performance.

Industry Context

The grant of stock options to a non-employee director is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of executive and director compensation packages to attract and retain talent and align their interests with long-term shareholder value.

Comparison to Industry Standards

• Granting stock options as part of non-employee director compensation is a widely accepted practice across various industries, including biotech, aligning with global benchmarks for corporate governance and incentive structures.
• The specific number of options (17,000) and the exercise price ($2.01) would typically be evaluated against peer companies of similar market capitalization and stage of development to assess competitiveness, though this filing alone does not provide sufficient data for such a detailed comparison.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of options to a director is intended to align the director's interests with long-term shareholder value creation, potentially leading to more focused decision-making for company growth.
• Employees: No direct impact mentioned, but consistent compensation practices for leadership can contribute to overall company stability and morale.

Next Steps

• The stock options will vest on the earlier of January 9, 2027, or the day prior to the next annual meeting of stockholders, subject to continued service.

Key Dates

Keywords

BioXcel Therapeutics, BTAI, Stock Options, Insider Transaction, Director Compensation, Form 4, Equity Grant, Corporate Governance